SEC Form 4 · accession 0001144204-15-059931
Cytosorbents Corp · CTSO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Al Kraus
Director
Period of report
Oct 15, 2015
Accepted (ET)
Oct 19, 2015 · 3:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001175151
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 15, 2015 | M | 6,774 | $0.875 | A | 62,520 | D | |
| Common StockF2,F3 | Oct 15, 2015 | S | 6,774 | $6.2182 | D | 55,746 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option | $0.875 | Oct 15, 2015 | M | 10,000 | D | Jun 25, 2008 | Jun 25, 2018 | Common Stock | 6,774 | 0 | D |
Explanation of responses
- F1Stock option exercise and open market sales pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- F2The price in column 4 is a weighted average price. The prices actually received by the reporting person in this transaction range from $6.20 to $6.26.
- F3The reporting person has provided to the issuer, and the issuer will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range reported.